echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > In the past 5 trading days, more than 100 listed companies have been investigated by institutions, and this pharmaceutical company has been investigated by institutions 5 times!

    In the past 5 trading days, more than 100 listed companies have been investigated by institutions, and this pharmaceutical company has been investigated by institutions 5 times!

    • Last Update: 2022-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    According to data treasure statistics, in the past five trading days (December 8 to December 14), about 142 listed companies in Shanghai and Shenzhen have been investigated
    by institutions.
    In the institutional research list, a total of 60 companies have been surveyed by more than 20 institutions, including Qiaqia Food, Nanwang Technology, Topstar, Huayang Group, etc
    From the perspective of the number of institutional surveys, Zhenbao Island has attracted much attention from institutions, with a total of 5 institutional surveys
    On December 16, Zhenbao Island announced that the company was investigated by institutions on December 15, 2022, and the institutions participating in the survey included Wanhe Securities, China Overseas Fund, Huaxia Pension, Shenzhen Maoyuan, Shanghai Chongshan, Oriental Marathon, Fu Quoc Chase, etc
    In the interactive session, the institution mainly focuses on the company's product layout, Chinese herbal medicine revenue, competitive advantage, and the status of companies in the industry
    In view of the recent high prices of some medicinal materials, the company believes that from the perspective of the supply and demand market, after liberalization, traditional Chinese medicine anti-epidemic will continue to be recognized to a certain extent, and it will be in a tight supply state for a period of time in the future, which will also stimulate the possibility of rising the price of traditional Chinese medicinal materials
    In addition, in terms of respiratory cold-related products that have attracted much attention recently, the company has related proprietary Chinese medicines and APIs of Chinese herbal medicines, and the oral preparations of proprietary Chinese medicines will have a recovery growth
    in the next 3-6 months.
    On the same day, Zhenbao Island announced that on December 14, the company also received a number of institutional surveys, including Huatai Berry Management, Ping An Asset Management, Huaan Fund, Anbang Asset, Oriental Marathon, etc
    In this Q&A session, the company's profit model, repurchase and equity incentives, formula granules, the impact of proprietary Chinese medicines on the pharmaceutical industry, and the direction of future development trends have attracted institutional attention
    Centralized procurement is a major challenge faced by pharmaceutical companies in recent years, and the company said that the current inter-provincial centralized procurement alliance of proprietary Chinese medicines has completed Hubei, Guangdong and Shandong, and the company has made strategic responses
    In the future, the company will actively participate
    in the centralized procurement of other provinces according to the variety and drug situation.
    In addition, in terms of formula granules, the company said that "because Jumbo Island is currently a participating shareholder, there is not much impact
    " On December 13, Jumbo Island also released a record of investor relations activities, and the company was surveyed
    by four institutions on December 13, 2022.
    In this round of institutional Q&A session, the institution mainly focused on the company's progress of innovative Chinese medicine drugs and the secondary development of traditional Chinese medicines, the response strategies for the centralized procurement and price reduction of proprietary Chinese medicines, the situation of formula granules, and the future promotion strategy of blood injection
    Among them, in terms of innovative Chinese medicine and secondary development of traditional Chinese medicine, the company replied that the two varieties with faster progress are Qingxian and stomach formula, and the other is Qiang Huosheng wet soup
    At present, the progress of R&D is in line with expectations
    In terms of secondary development of traditional Chinese medicine, the company carries out secondary development of existing core key products, carries out research on evidence-based medicine, standard improvement, new dosage forms, new specifications, new indications, etc.
    , so as to enhance the competitiveness of the drug market and extend the life cycle of drugs, all of which comply with relevant national regulations
    In addition, on December 9, Zhenbao Island announced that from December 8 to December 9, the company received research from Red Earth Innovation and other institutions
    From the interactive Q&A session, there are many similarities between the concerns of the organization and the issues mentioned above
    For the performance expectations in the next few years, the company said that with the country's friendly policies for traditional Chinese medicine injections, injection products are expected to have a certain recovery growth in the future, and with the lifting of medical insurance payment restrictions, oral preparations are also expected to have some room
    for improvement.
    In the field of Chinese medicinal materials, the current demand for medicinal materials of major Chinese medicine manufacturing enterprises is large, but the gross profit margin of Chinese medicinal materials is not high, and in terms of profit contribution, the gross profit margin of spot trading is currently about 5%, and the gross profit will be improved
    in the future with the development of different trading modes.
    According to the third quarter report of 2022, the company achieved a total operating income of 3.
    320 billion yuan in the first three quarters, a year-on-year increase of 22.
    77%; The net profit attributable to the parent was 153 million yuan, down 36.
    from the same period last year.
    Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
    to anyone.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.